Incidence of gastrointestinal malignancies increases in persons received eradication therapy for Helicobacter pylori: A cohort study

Author:

Kosunen Timo U.1,Nieminen Anna A.2ORCID,Kokkola Arto2,Arkkila Perttu3,Pukkala Eero45,Rautelin Hilpi6

Affiliation:

1. Department of Bacteriology and Immunology, Haartman Institute University of Helsinki Helsinki Finland

2. Department of Surgery Helsinki University Hospital and University of Helsinki Helsinki Finland

3. Department of Gastroenterology Helsinki University Hospital and University of Helsinki Helsinki Finland

4. Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research Helsinki Finland

5. Health Sciences Unit, Faculty of Social Sciences Tampere University Tampere Finland

6. Clinical Microbiology, Department of Medical Sciences Uppsala University Uppsala Sweden

Abstract

AbstractBackgroundLong‐term Helicobacter pylori infection increases the risk of gastric malignancies. Since the symptoms for H. pylori gastritis, as well as for several malignancies, may be nonexisting or highly unspecific, even H. pylori‐positive subjects with underlying malignancies may receive eradication therapy. The aim was to assess the incidence of gastrointestinal and various other malignancies in individuals after eradication therapy for H. pylori infection.Materials and MethodsA cohort of 217,554 subjects (120,344 women and 97,210 men), who had purchased specific combinations of drugs for H. pylori eradication therapy in 1994–2004, was identified by the Finnish National Prescription Registry and followed for cancer incidence until the end of 2008 (1.89 million person‐years at risk).ResultsA total of 22,398 malignancies were identified in the cohort. In both genders, for the first 6 months after drug prescription, the standardized incidence ratios (SIRs) were between 5 and 32 for gastric, colorectal, and pancreatic cancers, and 2 and 3 for several other malignancies. Although later on the SIRs of most malignancies fell rapidly, those of gastric noncardia and lung cancers remained elevated up to 5 years of follow‐up. The only SIRs below unity were seen in men for gastric cancers (cardia 0.61, 95% CI: 0.37–0.95; intestinal noncardia 0.74, 95% CI: 0.56–0.97) during the post‐therapy period covering years 5–15.ConclusionIncidence levels significantly above the population rates were detected for many malignancies. Although eradication of H. pylori may have a long‐lasting protective effect against gastric cancer, H. pylori therapy may postpone the detection of malignancies possibly underlying unspecific gastrointestinal symptoms. Therefore, it should be emphasized that the diagnostic work‐up for malignancies should not be stopped in case of detection and treatment of H. pylori infection.

Publisher

Wiley

Subject

Infectious Diseases,Gastroenterology,General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3